Shots:
- The sBLA submission is based on results from a P-II study evaluating the efficacy & safety of tislelizumab (200 mg, IV, q3w) as monothx in 80 patients with previously treated LA, unresectable or metastatic MSI-H or dMMR solid tumors
- The results demonstrated that the therapy treatment was consistent & durable across tumor types and EPs while 1EPs of the trial is ORR and 2EPS include time to response, DoR, DCR, and PFS as assessed by investigator & IRC, OS & evaluates the safety and tolerability
- Tislelizumab is a humanized IgG4 anti-PD-1 mAb specifically designed to minimize binding to FcγR on macrophages. The BLA marks 7th indication for tislelizumab
Click here to read full press release/ article | Ref: Business Wire | Image: BeiGene
The post BeiGene Reports NMPA’s Acceptance of sBLA for Tislelizumab to Treat MSI-H or dMMR Solid Tumors first appeared on PharmaShots.
